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Abstract
Study design Randomised double-blind factorial-design placebo-controlled trial.
Objective Urinary tract infections (UTIs) are common in people with spinal cord injury (SCI). UTIs are increasingly difficult
to treat due to emergence of multi-resistant organisms. Probiotics are efficacious in preventing UTIs in post-menopausal
women. We aimed to determine whether probiotic therapy with Lactobacillus reuteri RC-14+Lactobacillus GR-1 (RC14-
GR1) and/or Lactobacillus rhamnosus GG+Bifidobacterium BB-12 (LGG-BB12) are effective in preventing UTI in people
with SCI.
Setting Spinal units in New South Wales, Australia with their rural affiliations.
Methods We recruited 207 eligible participants with SCI and stable neurogenic bladder management. They were rando-
mised to one of four arms: RC14-GR1+LGG-BB12, RC14-GR1+placebo, LGG-BB12+ placebo or double placebos for
6 months. Randomisation was stratified by bladder management type and inpatient or outpatient status. The primary outcome
was time to occurrence of symptomatic UTI.
Results Analysis was based on intention to treat. Participants randomised to RC14-GR1 had a similar risk of UTI as those
not on RC14-GR1 (HR 0.67; 95% CI: 0.39–1.18; P= 0.17) after allowing for pre-specified covariates. Participants ran-
domised to LGG-BB12 also had a similar risk of UTI as those not on LGG-BB12 (HR 1.29; 95% CI: 0.74–2.25; P= 0.37).
Multivariable post hoc survival analysis for RC14-GR1 only vs. the other three groups showed a potential protective effect
(HR 0.46; 95% CI: 0.21–0.99; P= 0.03), but this result would need to be confirmed before clinical application.
Conclusion In this RCT, there was no effect of RC14-GR1 or LGG-BB12 in preventing UTI in people with SCI.
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Alterations in urogenital function following a spinal cord
injury (SCI) increase the susceptibility of this population to
urinary tract infections (UTIs). As a consequence, all UTIs
in people with SCI are considered complicated [1]. The
incidence of UTI in people with SCI is ~2 episodes per
year [2, 3]. Non-antibiotic alternatives like methenamine-
hippurate and cranberry tablets, commonly used to prevent
UTIs in this population, are ineffective [4].
Another challenge facing clinicians and persons with SCI
to manage UTIs is the high rate of colonisation of multi-
resistant organisms (MROs) within the population [5, 6].
Simple oral antibiotics are frequently ineffective, which
amplifies the health care and economic costs of treating
UTIs in this population. Regular antimicrobial prophylaxis
is not recommended as it leads to a two-fold increase in
MROs [7]. Hence, it is imperative that a non-antibiotic
prevention is found, as not to increase the antimicrobial
resistance burden [8].
Probiotics are defined as a preparation containing viable,
defined micro-organisms in sufficient numbers, which alter
the microflora (by implantation or colonisation) in a com-
partment of the host and thus exert beneficial health effects
[9]. A systematic review of trials in women concluded that
Lactobacillus rhamnosus GR-1 and Lactobacillus fermen-
tum RC-14, delivered either intravaginally or orally, were
efficacious in preventing recurrent UTIs [10]. In vitro stu-
dies have shown that biosurfactants produced by certain
Lactobacilli strains inhibit the adhesion of uropathogenic
bacteria to silicone rubber [11]. Clearance of vancomycin-
related enterococci in stool after treatment with L. rham-
nosus GG has also been reported [12]. Thus, literature
suggests that probiotics may have a role in preventing
UTIs.
Objectives
There are currently no known studies of oral probiotics and
their efficacy in the prevention of UTIs in people with SCI
and neurogenic bladder. We propose a randomised con-
trolled trial (RCT) to investigate the effectiveness of
combination oral probiotic therapy [L. reuteri RC-14+L.
rhamnosus GR-1 (RC14-GR1) and/or Lactobacillus
GG+Bifidobacterium BB-12 (LGG-BB12) capsules] to
prevent UTI in people with SCI compared to placebo. The
rationale being that the combination probiotics will have a
two-pronged approach of clearing MROs which is highly
prevalent in SCI persons as well as in preventing UTIs.
MRO clearance is beyond the scope of this manuscript
report.
Methods
ProSCIUTTU was a prospective multi-site randomised, dou-
ble-blind, double-dummy, placebo-controlled factorial design
trial conducted in the state of New South Wales (NSW),
Australia [13]. Prior to commencement, approval was granted
from a lead human ethics committee covering the eastern
seaboard of Australia. Research governance approval was
also granted in all hospitals involved in the trial. The trial was
registered with the Australian New Zealand Clinical Trials
Registry (ACTRN12610000512022). The trial protocol and
full methodology has previously been published, therefore we
will present a briefer version in this paper [13].
Participants
Participants were actively recruited from the database of all
past and current patients in each of the three specialist SCI
units in NSW (Prince of Wales Hospital, Royal North Shore
Hospital and Royal Rehabilitation Centre Sydney), including
their rural affiliations. Participants were over 18 years of age,
with SCI and stable neurogenic bladder management. Partici-
pants agreed not to take any other probiotics in addition to the
allocated intervention during the course of the study. Exclusion
criteria were complex bladder disturbances requiring surgical
intervention, known urinary tract calculi, having received
bladder education within the last 4 weeks, pre-existing infec-
tion on intervention commencement, known long-standing
osteomyelitis, long-term antibiotic therapy, adverse reaction to
yoghurt products, severe renal or hepatic failure, full
mechanical ventilation and immunosuppression. Participants
provided written informed consent before enrolment.
Interventions
Participants were enroled for a 6-month study period, which
included 24 weeks of treatment. Each randomised partici-
pant was required to take two capsules orally each day
consisting of either:
1. Group 1: RC14-GR1 (concentration per capsule is
5.4 × 109 colony-forming units)+LGG-BB12 (con-
centration per capsule is 7 × 109 colony-forming units)
2. Group 2: RC14-GR1 (concentration as above)
+matched placebo (no LGG-BB12)
3. Group 3: LGG-BB12 (concentration as above)
+matched placebo (no RC14-GR1)
4. Group 4: Double matched placebo capsules (no
RC14-GR1 and no LGG-BB12)
5. To ensure that there was no degradation of probiotics
during the entire duration of the trial, the capsules
were stored at −25 °C and tested at 12 monthly
intervals for organism numbers throughout the study.
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Outcomes
Primary outcome measure is the time from randomisation to
occurrence of first symptomatic UTI (primary endpoint)
(Fig. 1). Symptomatic UTI is not well -defined in the SCI
literature [14]. UTI for the purpose of our study was only
based on a combination of symptom(s) and microbiological
analysis of urine. Our criteria was based on a consensus
statement by the National Institute on Disability and Reha-
bilitation Research and a previous trial [4, 15]. Supplementary
Table 1 outlines the category of symptoms for the algorithm.
Participants who did not experience a symptomatic UTI were
censored at 6 months or when they withdrew from the trial.
Participants were assessed at baseline, 3 and 6 months,
supported by telephone calls every 2 weeks to confirm
intercurrent symptomatic UTI status. To evaluate quality of
life, the Short Form Health Survey (SF-36) was conducted at
baseline, study endpoint and 6 months. Microbiological
swabs of the rectum, nose and groin and a urine culture were
obtained at baseline, 3 months and 6 months. These samples
were analysed at a central laboratory and are beyond the
scope of this manuscript report. A urine culture was also
performed if participants developed symptoms of UTI. We
requested at all occasions for urine to be collected from a new
single use catheter or new suprapubic catheter. The endpoint
urine cultures were analysed at the participant’s local micro-
biological laboratory due to logistics and clinical reasons.
All participants were also given information about
symptoms of a UTI, contact numbers of researchers and the
participant’s SCI unit so they can contact their SCI
physician.
Sample size
In our previous RCT with the same study population [4], 45%
of participants had a symptomatic UTI within 6 months. To
have 80% power to detect [at 5% two-sided significance
level] a reduction to 30% in the treatment group requires a
total sample size of 350. Allowing for a 5% loss to follow-up
a final sample size of 372 is required, with 93 participants
randomly allocated to each of the four study groups.
Randomisation
A simple computer-generated randomisation protocol was
used. Randomisation was stratified by bladder management
type (indwelling urethral/suprapubic vs. intermittent cathe-
ters vs. condom drainage/reflex voiding) and inpatient/out-
patient status. Randomisation occurred after informed
consent and baseline measures were obtained from the
participant. The washout period and compliance check with
placebo, as stated in the protocol, were carried out for the
first 14 patients and all were found to be 100% compliant.
However, due to logistical difficulties and to reduce tra-
velling costs for researchers, the protocol was amended and
the washout and compliance check were abandoned. One
central pharmacy was responsible for the assignment and
distribution of the intervention for the entire study.
Blinding
All four treatment regimens were indistinguishable by
appearance and taste. All clinical staff, researchers and
participants remained blind to treatment allocation
throughout the trial. Clinicians (BBL, GHW, JK, KC and S-
LT) who had patients in the study were kept blinded at all
times including during the blinded analysis phase. Micro-
biological assessments were available to investigators and
were released if clinicians on the study felt it would assist
with medical management. All staff was blinded to alloca-
tion for the assessment of symptomatic outcomes. An audit
of randomisation, product allocation and dispensing stock
was performed at the completion of the study.
Statistical methods
Analysis of all outcomes was by intention to treat. Primary
outcome was analysed using survival analysis. The log-rank
test statistic was used to assess the significance of the
unadjusted effect of a variable in preventing UTI. Kaplan–
Meier survival curves, hazard ratios (HR) and their 95%
confidence intervals (CI) were used to summarise results of
the effect of RC14-GR1 and LGG-BB12 on time to primary
endpoint. Cox regression modelling was performed to test
the effect of each treatment while allowing for the other. To
determine which variables were clinically correlated with
UTI in the SCI population, a survey was sent out to four
investigators (BBL, GHW, KC and SAR). They were
requested to rate the association of a list of variables col-
lected for the trial as strong, moderate or weakly associated
with UTI. The variables gender, inpatient status, complete-
ness of injury (American Spinal Injury Association Impair-
ment Scale Grade A) [16], bladder management, time since
injury, current urinary tract stone and UTI in the last
6 months were considered to be moderate to strongly asso-
ciated with UTI. Analysis was performed using SAS 9.3.
Results
Baseline data
Study participants were recruited from April 2011 to Feb-
ruary 2014.
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Four-hundred and ninety-seven participants were
approached via correspondence, telephone contact or in
person. Three-hundred and fifty participants were interested
and were screened for eligibility. Of the 350 participants
screened, 10 did not have neurogenic bladder and 76 either
did not want or could not cease excluded medications like
antibiotics and their current probiotics (Fig. 2—participant
flow). Thirty-nine were excluded due to criteria such as
complex bladder disturbance or chronic pressure ulcers.
All 207 participants who were randomised were analysed
by original group assignment (intention to treat). Partici-
pants had a mean age of 49.1 years (range 19–82 years) and
were predominantly male (79%). Forty-seven percent were
tetraplegics and 51% had complete injury (American Spinal
Injury Association Impairment Scale Grade A). Sixty-
percent of participants had a suprapubic or indwelling
urethral catheter as part of neurogenic bladder management.
The median time since SCI was 7 years (range 10 days to 61
years).
There were no clinically important differences between
the treatment groups at baseline in the characteristics mea-
sured (Table 1).
Outcomes and estimation
Fifty-three of 207 participants met study endpoint UTI, as
follows: 14 in Group 1, 8 in Group 2, 15 in Group 3 and 16
in Group 4. A further 20 participants had symptomatic but
not study endpoint UTI; 5 of these had fever. Of the
53 study endpoint UTI participants, 22 had febrile UTIs. As
Fig. 1 Definition of primary
endpoint UTI for ProSCIUTTU
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a consequence of their endpoint UTI, 3 participants devel-
oped urosepsis, one participant was diagnosed with pyelo-
nephritis and one participant was diagnosed with orchitis.
All except one participant who met the study endpoint
utilised catheters to empty their bladder. In terms of UTI
recurrence in the 53 participants, 11% (6/53) had a sub-
sequent study endpoint UTI and 6% (3/53) had a further
two study endpoint UTIs within the 6-month duration of the
study.
For urine cultures that met study endpoint, 36/53 urine
grew gram negative organisms with the predominant spe-
cies being Escherichia coli.
After 6 months of oral probiotics therapy, the unadjusted
analysis (Table 2) showed no significant effect on symp-
tomatic UTI of RC14-GR1 (HR 0.71, 95% CI: 0.41–1.23;
P= 0.22) or LGG-BB12 (HR 1.27, 95% CI: 0.74–2.18;
P= 0.39). The Kaplan–Meier survival curves for partici-
pants on active treatment with RC14-GR1 (groups 1 and 2
combined) and those not on RC14-GR1 (groups 3 and 4)
are shown in Fig. 3. The curves for those on active
treatment with LGG-BB12 (groups 1 and 3) and those
not on LGG-BB12 (groups 2 and 4) are shown in
Fig. 4.
The only statistically significant predictor of a future UTI
was whether there was a UTI in the preceding 6 months
(log-rank χ2= 12.24, df= 2; P= 0.002), and there was
some evidence that an incomplete injury may be protective
against UTI (P= 0.052). There was no statistically sig-
nificant relationship between UTI-free survival and inpa-
tient/outpatient status, bladder management, gender, age
and time since injury. As the number of participants who
were found to have urinary stones was low (eleven), it was
difficult to predict the effect of this variable on UTI-free
survival.
Multivariable analysis using Cox proportional hazards
regression (Table 3), adjusting for pre-specified variables
Fig. 2 Consort participant flow
diagram
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gender, inpatient status, bladder management, completeness
of injury, time since injury and UTI in six months
prior to study, showed no statistically significant effect of
RC14-GR1 compared to no RC14-GR1 (HR 0.67, 95% CI:
0.39–1.18; P= 0.17) or of LGG-BB12 compared to no
LGG-BB12 (HR 1.29, 95% CI: 0.74–2.25; P= 0.37).
Ancillary analysis
The Kaplan–Meier survival curves appeared to show
longer UTI-free survival for RC14-GR1 by itself (Group 2)
than the other groups (Fig. 5). Post hoc multivariable
analysis was therefore carried out for RC14-GR1
alone pooled against the three other treatment groups
using Cox proportional hazards regression. There was a
statistically significant effect of RC14-GR1 alone
after adjusting for the same covariates (HR 0.46, 95% CI:
0.21–0.99; P= 0.03).
Analysis was conducted for the 184 participants who
answered the SF-36 questionnaire at baseline and end of
treatment. There was no statistically significant difference
between the baseline and end-of-treatment quality of life of
participants in any of the trial groups under the eight dif-
ferent domains of the SF-36 (physical functioning, role
physical, role emotion, social functioning, pain, mental
health, vitality and general health).












n (%) n (%) n (%) n (%)
Characteristics N 101 106 104 103
Participant location at
recruitment
Inpatient 19(19) 21(20) 22(21) 18(17)
Outpatient 82 (81) 85(80) 82(79) 85(83)
Gender
Female 18(18) 26(25) 18(17) 26(25)
Male 83(82) 80(75) 86(83) 77(75)
Bladder management
Indwelling catheter 9(9) 12(12) 12(12) 9(8)
Suprapubic catheter 51(50) 51(48) 49(47) 53(51)
Clean intermittent
catheters
34(34) 37(35) 38(36) 33(32)
Reflex voiding
(±condom)
7(7) 6(5) 5(5) 8(8)
Level of injury
Cervical 46(45) 51(48) 48(46) 49(44)
Thoracic 43(43) 50(47) 48(46) 45(47)
Lumbar 12(12) 5(5) 8(8) 9(9)
Completeness of injurya
Complete 53(52) 53(50) 55(53) 51(50)
Incomplete 48(48) 53(50) 49(47) 52(50)
Presence of urinary
stone
None 98(97) 98(92) 97(93) 99(96)
Present 3(3) 8(8) 7(7) 4(4)
Age (years)
<25 6 (6) 9(8) 8(8) 7(7)
25 to <45 33(33) 34(32) 37(36) 30(29)
45 to <65 48(47) 43(41) 44(42) 47(46)
>65 14(14) 20(19) 15(14) 19(18)
Time since injury
<2 years 27(27) 30(28) 29(28) 28(27)
2–20 years 52(51) 43(41) 48(46) 47(46)
>20 years 22 (22) 33(31) 27(26) 28(27)
AIS classificationa
A 53(52) 53(50) 55(53) 51(50)
B 17(17) 19(18) 22(21) 14(14)
C 14(14) 19(18) 14(13) 19(18)
D 17(17) 15(14) 13(13) 19(18)
E 0 0 0 0
Urinary tract infection in
the last 6 months prior to
trial













n (%) n (%) n (%) n (%)
1 31(31) 23(22) 19(18) 35(34)
2 to 5 26(26) 33(31) 32(31) 27(26)
More than 5 6(6) 6(6) 4(4) 8(8)
Hospitalisation prior to
trial in last 6 months
0 91(90) 91(86) 91(87) 91(88)
1 8(8) 12(11) 9(9) 11(11)
2–5 1(1) 3(3) 3(3) 1(1)
More than 5 1(1) 0 1(1) 0
General practitioner
visit for urinary tract
infection before trial
None 60(59) 65(61) 69(66) 56(54)
1 22(22) 12(11) 10(10) 24(23)
2–5 13(13) 26(25) 19(18) 20(20)
5 or more 6(6) 3(3) 6(6) 3(3)
aAmerican Spinal Injuries Association (ASIA) Impairment Scale (AIS)
for neurological classification of SCI definition [16]
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Harms
Side effects from either intervention were infrequent. The
double placebo group appeared to have more adverse events
than the other groups. The majority of adverse events were
due to bowel complaints, such as bowel accidents and
increased frequency of bowel movement. Other adverse
events reported were symptoms of UTI, abdominal cramps,
blocked urinary catheter and groin rash. Two deaths in the
study were unrelated to trial intervention as they were due
to respiratory failure and biliary sepsis (Supplementary
Table 2).
Discussion
In this double-blind, double-placebo RCT, there was no
effect of RC14-GR1 or LGG-BB12 in preventing UTI in
Table 2 Unadjusted effects of all
pre-specified covariates,
including RC14-GR1 and LGG-
BB12, on UTI-free survival
Covariates Hazard ratio (95% CI) P-value (log rank)
RC14-GR1
Placebo 1
Active 0.71 (0.41, 1.23) 0.22
LGG-BB12
Placebo 1
Active 1.27 (0.74, 2.18) 0.39
Participant location at recruitment
Inpatient 1 0.40
Outpatient 0.76 (0.40, 1.45)
Gender
Female 1 0.82
Male 1.08 (0.56, 2.10)
Bladder management
Indwelling catheter 1 0.40
Suprapubic catheter 0.68 (0.29, 1.57)
Intermittent catheter 0.83 (0.35, 1.97)
Reflex voiding (±condom) 0.21 (0.03, 1.70)
Level of injury
Cervical 1 0.63
Thoracic 0.84 (0.48, 1.47)
Lumbar 0.59 (0.18, 1.95)
Completeness of injurya
Complete 1 0.052
Incomplete 0.58 (0.33, 1.01)
Current renal/bladder stone
None 1 0.99
Present 0.99 (0.31, 3.17)
Age (years) 0.99 (0.97, 1.01) 0.43
Time since injury (years) 0.99 (0.98, 1.02) 0.64
ASIA levela
A 1 0.17
B 0.67 (0.31, 1.44)
C 0.73 (0.34, 1.58)
D 0.35 (0.12, 0.98)
UTI 6 months prior to trial
No 1 0.002
Yes 1.21 (1.08, 1.35)
aAmerican Spinal Injuries Association (ASIA) Impairment Scale (AIS) for neurological classification of SCI
definition [16]
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people with SCI using a factorial design. The post hoc
analysis of RC14-GR1 (alone) suggests the potential that
RC14-GR1 may be a beneficial organism for preventing
UTI when used alone. A priori, this study was not designed
to test this hypothesis.
Our results for LGG-BB12 are consistent with anything
from a protective effect against UTI (lower 95% confidence
limit for HR: 0.74) to increasing the risk of UTI (upper 95%
confidence limit for HR: 2.18). The possibility of LGG-BB12
increasing the likelihood of a UTI would indicate that not all
probiotics are necessarily beneficial in all circumstances,
which raises questions about mixed organism probiotics being
used in the community to prevent UTI. RC14-GR1 is an
organism with prior urinary prophylactic data [10], while
LGG is an organism where there is more data about MRO
colonisation reduction [12]. More task selectivity for probiotic
organisms is likely to be necessary, as well as a better
understanding of the dosages required for UTI prevention.
Fig. 3 Kaplan–Meier curve for
RC14-GR1 compared to no
RC14-GR1
Fig. 4 Kaplan–Meier curve for
LGG-BB12 compared to no
LGG-BB12
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Our results confirm the relationship between previous
UTIs and increased likelihood of recurrences. In our cohort,
if participants had at least one UTI in the preceding
6 months, their risk of having a subsequent UTI was
increased by 21% in the following 6-month period (Tables 2
and 3). This concurs with findings from the previous
SINBA study [4]. One critique of our study could be the
high number of participants (>60%) utilising either an
Table 3 Adjusted effects of
RC14-GR1 and LGG-BB12
treatments and other covariates
on UTI-free survival
Covariates Hazard ratio (95% CI) P-value (Likelihood ratio test)
RC14-GR1
Placebo 1 0.17
Active 0.67 (0.39, 1.18)
LGG-BB12
Placebo 1 0.37
Active 1.29 (0.74, 2.25)
Participant location at recruitment
Inpatient 1 0.57
Outpatient 0.79 (0.34, 1.81)
Gender
Female 1 0.78
Male 1.10 (0.55, 2.20)
Bladder management
Indwelling catheter 1 0.95
Suprapubic catheter 0.67 (0.26, 1.76)
Intermittent catheter 0.78 (0.31, 1.98)
Reflex voiding (±condom) 0.34 (0.04, 3.01)
Completeness of injurya
Complete 1 0.03
Incomplete 0.52 (0.29, 0.94)
Time since injury 0.99 (0.97, 1.02) 0.48
UTI 6 months prior to trial 1.24 (1.10, 1.40) 0.002
aAmerican Spinal Injuries Association (ASIA) Impairment Scale (AIS) for neurological classification of SCI
definition [16]
Fig. 5 Kaplan–Meier curve for
RC14-GR1 vs. three other
treatment groups
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indwelling urethral or suprapubic catheter. Indwelling ure-
thral and suprapubic catheters have been associated with
higher rates of urinary tract complications including UTIs
[17]. Intermittent self-catheterisation rates in this cohort
were only 30%. However, Cameron reported that only 20%
of SCI patients on intermittent catheterisation remained on
this form of management after 30 years with the majority
reverting to use of an indwelling urethral/suprapubic
catheter [18].
One of the strengths of the study is obtaining urinary
microbiological confirmation for participants who met the
endpoint criteria for “symptomatic UTI”. This is despite their
endpoint urine analysis not being performed in the central
laboratory used by the study. Due to logistical and clinical
reasons, the endpoint urine culture was analysed at the par-
ticipant’s local microbiological laboratory. There was one
participant who did not meet urinary microbiological criteria
for “symptomatic UTI”. That participant was classified as
meeting study endpoint based on symptoms and presence
of pyuria in the urine analysis. This decision was made
following a discrepancy between two blinded assessors
(S-LT and BBL) leading to verification by a third blinded
assessor (KC). There was another participant who met end-
point criteria but was considered not appropriate by KC as
the participant had hypothermia instead of a fever, no Cate-
gory 2 urinary symptoms and a fractured neck of femur to
account for autonomic dysreflexia and abdominal pain.
The overall event rate was also much lower than expected
from our previous research [4]. This could be due to the
stringency of our endpoint criteria, needing to meet both
symptoms and microbiological confirmation. In our previous
trial, endpoint was based on symptoms and positive urine
dipstick or presence of pyuria. For this trial we wanted to
achieve best practice in UTI treatment. If we did not insist on
urinary microbiological confirmation, we would have had an
additional 20 participants meeting endpoint criteria.
In our sample size calculation, we predicted 45% of
participants in the control group would develop a sympto-
matic UTI within 6 months but only 26% of the total par-
ticipants did. With 103 per group (active RC14-GR1 vs. no
RC14-GR1 OR active LGG-BB12 vs. no LGG-BB12) we
had 80% power to detect a reduction from 34% UTI in the
control to 17% in the treated group at the two-sided 5%
significance level (these rates would give 53 expected UTIs
in total). By this calculation the treatment would have
needed to halve the UTI rate, not just reduce it by 33%
proportionately (from 45% to 30%).
The major limitation of our study was the failure to
recruit the targeted 372 participants. The main reason
was insufficient funding for such a geographically dis-
persed cohort of participants. Trial funding only
accounted for participants who lived in close proximity
(around 35 km) to each of the SCI units located in
metropolitan Sydney. We ended up recruiting partici-
pants in several regional and remote areas outside of
metropolitan Sydney. This was partly due to competition
from other concurrent SCI trials which limited access to
eligible metropolitan participants. In retrospect, more
detailed costing should have been performed in order to
apply for more appropriate funding. Travel costs con-
sumed a significant amount of resources. The cost of
microbiological analysis also exceeded the budget. Some
potential study participants were reluctant to give up
yoghurt or cease their current probiotics or antibiotic
regime for the duration of study. It is possible that more
recruitment success could have been achieved by invol-
ving additional national or international partners.
Nevertheless, this is the largest randomised trial of oral
probiotics in a neurogenic bladder population.
Another limitation of our study is not following up
participants after trial completion (e.g. 3 or 6 months) to see
whether their incidence of UTI changed.
We cannot compare the results of our study to other
studies as there is no other RCT of oral probiotics in the
neurogenic bladder population [19]. We are aware of a
Cochrane review reporting low evidence of probiotics in
preventing UTIs in adults and children [20]. Kontiokari has
previously reported in an RCT that cranberry was more
effective than a Lactobacillus GG drink in preventing UTIs
in women [21]. Beerepoot reported that oral capsules of L.
rhamnosus GR-1 and L. reuteri RC-14 taken for 12 months
did reduce the mean number of symptomatic UTI in post-
menopausal women, however did not meet the non-
inferiority criteria when compared to trimethoprim-
sulfamethaxole [22].
We have not been able to demonstrate that RC14-GR1 or
LGG-BB12 is effective in preventing UTI in people with
SCI. There is the possibility that RC14-GR1 when used
alone may be beneficial, but this finding is hypothesis
generating only, due to post hoc analysis. Our study results
indicate that the clinical use of probiotics should be more
selective and specific. Further research into dosages as well
as task selectivity of probiotics should be conducted in the
future.
Data archiving
The UTI symptomatic data is being made available to the
ISCoS Datasets committee in a de-identified manner to assist
with ISCoS UTI data definitions and Bowel data definitions.
Records will be archived at NEURA for 15 years.
Registration
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